Advertisement
UK markets closed
  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     
  • FTSE 250

    19,719.37
    -80.35 (-0.41%)
     
  • AIM

    754.69
    -0.18 (-0.02%)
     
  • GBP/EUR

    1.1634
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.2432
    -0.0021 (-0.17%)
     
  • Bitcoin GBP

    52,138.49
    -1,488.27 (-2.78%)
     
  • CMC Crypto 200

    1,398.52
    -25.58 (-1.80%)
     
  • S&P 500

    5,051.60
    -18.95 (-0.37%)
     
  • DOW

    38,354.68
    -149.01 (-0.39%)
     
  • CRUDE OIL

    82.95
    -0.41 (-0.49%)
     
  • GOLD FUTURES

    2,336.80
    -5.30 (-0.23%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • CAC 40

    8,091.86
    -13.92 (-0.17%)
     

How Did Bausch + Lomb’s Top Products Perform in 3Q17?

In 3Q17, Valeant Pharmaceuticals’ Bausch + Lomb’s Soflens generated revenues of $83 million, which was ~5% higher on a YoY basis and ~9% higher QoQ.